This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Evox Therapeutics completes £69.2 million Series C financing

Evox Therapeutics completes £69.2 million Series C financing

18 Feb 2021

18th Feb 2021 Financing round significantly oversubscribed by both new and existing investors Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round. The financing was... Read more

Exscientia & University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Exscientia & University of Oxford announce partnership to develop treatments for Alzheimer’s disease

11 Feb 2021

Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease  Oxford: Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease... Read more

Immunocore Announces Pricing of Upsized Initial Public Offering

Immunocore Announces Pricing of Upsized Initial Public Offering

05 Feb 2021

Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an... Read more

Vaccitech Doses 1st Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP300 immunotherapeutic candidate for Chronic HBV

Vaccitech Doses 1st Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP300 immunotherapeutic candidate for Chronic HBV

01 Feb 2021

Oxford, UK – 1st February 2021 – Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose... Read more

Mobile laboratories use LamPORE COVID-19 test, UK Government LamPORE evaluation report shows high accuracy

Mobile laboratories use LamPORE COVID-19 test, UK Government LamPORE evaluation report shows high accuracy

29 Jan 2021

Mobile COVID-19 testing laboratories containing Oxford Nanopore’s LamPORE test are now being deployed in a pilot programme, to support testing efforts, including in remote locations. There are four mobile LamPORE units, currently located in Aberdeen, Telford, Brent and Newbury — where they are being used to support local testing services. This week the first unit to arrive in Scotland started testing in Aberdeen. The unit will move around the... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More